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Since aging is considered the most risk factor for sporadic Alzheimer’s Disease (AD), 
the age-related impairment of the immune system (immunosenescence), based on a 
chronic oxidative-inflammatory stress situation, could play a key role in the development 
and progression of AD. Although AD is accompanied by systemic disturbance, reflecting 
the damage in the brain, the changes in immune response and redox-state in different 
types of blood cells in AD patients have been scarcely studied. The aim was to analyze 
the variations in several immune functions and oxidative-inflammatory stress and dam-
age parameters in both isolated peripheral neutrophils and mononuclear blood cells, 
as well as in whole blood cells, from patients diagnosed with mild (mAD) and severe 
AD, and of age-matched controls (elderly healthy subjects) as well as of adult controls. 
The cognitive decline of all subjects was determined by Mini-Mental State Examination 
(MMSE) test (mAD stage was established at 20 ≤ MMSE ≤ 23 score; AD stage at <18 
MMSE; elderly subjects >27 MMSE). The results showed an impairment of the immune 
functions of human peripheral blood neutrophils and mononuclear cells of mAD and AD 
patients in relation to healthy elderly subjects, who showed the typical immunosenes-
cence in comparison with the adult individuals. However, several alterations were only 
observed in severe AD patients (lower chemotaxis, lipopolysaccharide lymphoprolifer-
ation, and interleukin (IL)-10 release; higher basal proliferation, tumor necrosis factor 
(TNF)-α release, and IL-10/TNF-α ratio), others only in mAD subjects (higher adherence), 
meanwhile others appeared in both mAD and AD patients (lower phytohemaglutinin 
lymphoproliferation and higher IL-6 release). This impairment of immune functions could 
be mediated by: (1) the higher oxidative stress and damage also observed in blood cells 
from mAD and AD patients and in isolated neutrophils [lower glutathione (GSH) levels, 
high oxidized glutathione (GSSG)/GSH ratio, and GSSG and malondialdehyde contents], 
and (2) the higher release of basal pro-inflammatory cytokines (IL-6 and TNF-α) found in 
AD patients. Because the immune system parameters studied are markers of health and 
rate of aging, our results supported an accelerated immunosenescence in AD patients. 
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We suggest the assessment of oxidative stress and function parameters in peripheral 
blood cells as well as in isolated neutrophils and mononuclear cells, respectively, as 
possible markers of AD progression.
Keywords: alzheimer’s disease, immunosenescence, immune function, oxidative stress, inflammation, blood 
cells, neutrophils, mononuclear cells
Given that aging is accompanied by a decline of the nervous 
and the immune systems, as well as of their communication 
(24), which contributes to the deterioration of homeostasis and 
health, AD can be understood in the context of aging (25). Since 
advanced age is considered the most consistent risk factor for 
sporadic AD (1), the age-related dysregulation of the immune 
system, which is denominated immunosenescence, should be 
considered to understand the development of this pathology 
(11, 16, 17, 25–27). Immunosenescence involves restructur-
ing changes in both innate and adaptive immune functions, 
which negatively affect the health of older adults, increasing 
susceptibility to infections and mortality (24, 28). Thus, there 
is an age-related decrease in several leukocytes functions, such 
as phagocytosis, chemotaxis, or stimulated proliferation, as well 
as an increase in other functions, such as adherence capacity to 
tissues and spontaneous lymphoproliferations, among others 
(24, 28–30). In AD patients, several immune functions are 
hampered in relation to healthy individuals with the same 
chronological age (8, 11, 19, 31–34), suggesting that this immune 
deterioration may be considered as a pathogenically relevant 
factor in this disease (33). Thus, it is assumed the advanced 
immunosenescence in AD patients, with remarkable immuno-
logical changes compared to healthy elderly subjects, which could 
contribute to AD pathology (11, 16, 17, 26, 33). Among these 
changes in AD patients the most relevant have been observed in 
the adaptive immune system. In fact, as also occurs in immu-
nosenescence, several authors have reported changes in T and 
B lymphocyte differentiation and subpopulation distribution in 
peripheral blood of AD subjects, as well as an altered proliferative 
T lymphocytes response (11, 33, 34). Nevertheless, the results are 
inconsistent since increased or decreased lymphoproliferation 
and percentages in T and B lymphocytes, as well as no alterations 
in these immune parameters have been detected in AD patients 
(11, 33, 34). Regarding innate immunity, abnormalities in the 
function of natural killer (NK) cells (31, 32), a decreased phago-
cytosis of Aβ in peripheral macrophages (19), and an altered 
release of pro-inflammatory cytokines [e.g. interleukin-(IL)-6, 
tumor necrosis factor (TNF)-α, etc.] (8) have been shown in AD 
patients in relation to age-matched controls. However, the data 
of human studies are still scarce, preliminary, and contradictory.
According to the oxidation–inflammation theory of aging, the 
basis of immunosenescence is a chronic oxidative-inflammatory 
stress situation (a progressive imbalance between higher endog-
enous levels of oxidant and inflammatory compounds and lower 
antioxidant and anti-inflammatory defenses) (24, 28). In fact, 
immune cells continuously generate oxidants and inflammatory 
compounds to carry out their defensive functions; however, if 
the overproduction of oxidant compounds is not well-controlled 
by the antioxidant defenses, an alteration occurs in the redox 
inTrODUcTiOn
Alzheimer’s disease (AD) is the most common neurodegenerative 
disorder and one of the major causes of senile dementia in later life. 
Epidemiological studies have revealed that AD is a multifactorial 
disease, with a complex interplay of environmental and genetics 
factors, which helps explain its variable clinical presentation (1, 
2). Traditionally, AD has been classified into hereditary and spo-
radic forms. The hereditary form is linked with several genes and 
typically presents an earlier age of onset. By contrast, the sporadic 
form, which is the most common cause of AD (>95% of cases), has 
a later age of onset and a stronger association with aging, the major 
risk-incurring variable (1, 2). Due to the increase in mean life span, 
this pathology is exponentially increasing and is estimated that the 
prevalence of AD may reach >115 million worldwide by 2050 (3). 
Despite the enormous social, economic and health care impact, 
public health care systems do not have the medical therapies 
necessary to address AD. Moreover, the diagnosis of individual 
with early AD is not easy, and it is usually diagnosed in late stages 
(even postmortem), by which time the available treatments are not 
effective (4). For this reason, it is crucial to identify biomarkers of 
early diagnosis of AD that can help in the development of effective 
therapeutics and prevention methods.
Neuropathologically, AD is a progressive and irreversible 
brain disorder characterized by the extracellular accumulation of 
amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles 
(NFTs) of hyperphosphorylated tau protein, associated with neu-
ronal cell death and synaptotoxicity (5). Additional changes such 
as brain atrophy, mitochondrial dysfunction, increase in oxidative 
stress, and neuroinflammation can also occur in the brains of peo-
ple with AD (6, 7). However, the mechanism of AD pathogenesis 
and progression still remain unclear. During the last few years, 
a higher number of studies have demonstrated that AD is also 
accompanied by a systemic disturbance, reflecting the damage in 
the brain (8–10). Thus, several studies support the involvement 
of an immune-related systemic alteration in AD, which includes 
changes in both innate and adaptive immune systems (11–15). 
Given the bidirectional communication between the immune and 
the nervous systems, and due to how the mediators of peripheral 
immune cells can influence the central nervous system (CNS) 
(16), it is not surprising that the age-related immunological vari-
ations can modify this neuroimmune communication network, 
contributing to the progressive cognitive impairment in AD (16). 
Indeed, numerous studies have shown changes in the distribu-
tion and reactivity of immune cells in the blood of AD patients 
(12, 17–21). This seems to cause a chronic inflammation in the 
periphery, which can be propagated through CNS immune cells, 
leading to neuroinflammation, which contributes to the cognitive 
deficits associated with AD (16, 22, 23).
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balance, leading to an oxidative stress situation, which causes 
oxidative damage in biomolecules (e.g., lipids, proteins, etc.), 
inducing remarkable negative consequences on cellular func-
tioning (24, 28). In addition, the chronic inflammation, which 
is characterized by excessive production and release of pro-
inflammatory cytokines and chemokines, also leads to signaling 
cascades that trigger the production of oxidant compounds and 
depletion of antioxidants (35, 36). Therefore, since oxidation and 
inflammation are interlinked processes, an active inflammatory 
response by immune cells can lead to cellular damage due to 
oxidant overproduction, which can also recruit other inflamma-
tory cells amplifying the cellular damage (35, 36). In this context, 
there is much evidence that indicates the strong involvement 
of inflammation and oxidative stress and damage in the onset, 
progression, and pathogenesis of AD (37–40). Thus, as occurs 
in aging, an enhanced oxidative stress has been observed in the 
brain (39, 40), as well as in peripheral tissues and cells (e.g., blood 
cells) (27, 41, 42) from AD patients. Indeed, many studies show 
both overproduction of oxidant compounds and impairment of 
antioxidant systems, as well as increased of oxidative damage 
(e.g., lipid peroxidation, proteins and DNA oxidation) in several 
brain regions of patients with both severe AD and mild cogni-
tive impairment (MCI) (40, 43, 44). These markers of oxidative 
damage were also detected in high levels in peripheral blood 
and cerebrospinal fluid (CSF) obtained from both MCI and AD 
patients, together with decreased plasma levels of non-enzymatic 
antioxidants and impaired activity of antioxidant enzymes. 
Moreover, peripheral levels of the pro-inflammatory cytokines 
(e.g., IL-6 or TNF-α) have been described to be higher, whereas 
anti-inflammatory cytokine levels (e.g., IL-10 and IL-4) are lower 
in patients with AD compared to age-matched controls (27, 42, 
43, 45–47). Interestingly, the fact that high levels of peripheral 
markers of oxidative-inflammatory stress were also detected in 
individuals with MCI, support the hypothesis that oxidative stress 
and inflammation are early events in the pathogenesis of AD, 
and precede Aβ deposit and onset of AD symptoms, as has been 
seen in experimental models of AD (48, 49). However, although 
several studies have evaluated oxidative stress parameters in both 
the early and advanced stages of human AD, the findings are 
controversial, as well as the relation between oxidative stress and 
cognitive performance, in mild and severe AD subjects, not yet 
being fully understood.
The use of animal models is particularly useful to study the 
molecular mechanisms involved in the development of AD and 
to identify potential therapeutic targets. In the last few decades, 
several transgenic animal models of AD have been developed 
to reproduce the neuronal pathology and behavioral symp-
tomatology of human AD. The triple-transgenic mouse model 
(3xTg-AD) represents a unique animal model that closely mim-
ics neuropathological manifestations, Aβ-plaques, and NFTs, in 
an age-dependent and region-specific manner like those in the 
human AD brain (50). Interestingly, as occurs in aging, it has been 
described that 3xTg-AD mice also suffer a pronounced and accel-
erated impairment in the neuroimmune network (16, 26), as well 
as a marked deterioration of several immune functions and an 
increased oxidative stress in different types of immune cells (e.g., 
peritoneal leukocytes) in comparison to control mice (16, 26, 51, 
52). These alterations were observed in both early and advanced 
stages of the AD neuropathology, as well as before the onset 
establishment of AD (16, 26, 51, 52). Given that these changes are 
characteristics of prematurely and chronologically aged subjects 
(28, 30, 53), the premature immunosenescence observed in the 
3xTg-AD mice at early stages of AD could explain the shorter 
life span also observed in these animals (52). Interestingly, the 
immune functions of peritoneal leukocytes of mice have been 
found to possess similar age-related evolutions to those observed 
in human circulating immune cells (30). Therefore, since immune 
functions are good markers of the rate of aging, and their analysis 
allows the early identification of premature and accelerated aging 
in humans (28, 30), the assessment of these parameters could be 
useful peripheral markers of the prodromal and preclinical states 
of AD (52).
It is also important to note that the most of studies performed 
in peripheral blood cells, have been carried out using mainly 
isolated peripheral mononuclear cells (95% lymphocytes and 
5% monocytes), which are the most commonly used cells in 
the clinical setting. However, there are a few studies in which 
changes in immune function and redox status have been assessed 
in isolated phagocytes. Since these cells (e.g., neutrophils and 
macrophages) have been suggested to be the main cells responsi-
ble for the chronic oxidative-inflammatory stress associated with 
immunosenescence (28, 54), they could provide a helpful sample 
to clarify the molecular mechanisms underlying the impairment 
of the immune system throughout of AD progression. Moreover, 
blood, and particularly circulating leukocytes, reflects the major 
physiological changes in various body organs and systems (47). 
Therefore, the use of blood cells seems to be more useful in assess-
ing markers that are analyzed in CSF, as well as identifying new 
markers that could be predictive of AD. Thus, it is possible that 
the assessment of these immune function parameters in the dif-
ferent types of peripheral blood immune cells, together with the 
evaluation of their oxidative-inflammatory state, could be useful 
early peripheral markers of the progression of AD in humans. 
However, this kind of study in different stages of human AD is 
still a subject that has scarcely been explored.
With the above in mind, the aim of the present work was to 
study the changes in several immune functions and inflamma-
tory-oxidative stress and damage parameters in different types 
of human blood immune cells at early and advance stages of AD 
progression. To address this study, we performed assays on both 
isolated peripheral polymorphonuclear (PMN) and mononuclear 
blood leukocytes, as well as in whole blood (WB) cells, from 
patients diagnosed with mild and severe AD, and age-matched 
controls (elderly healthy subjects) as well as adult controls.
MaTerials anD MeThODs
subjects and clinical classification
For this cross-sectional study, a total of 102 volunteers were selected 
and divided into four experimental groups: adult healthy subjects 
(n = 20), elderly healthy individuals (n = 38), mild AD (mAD) 
patients (n = 26), and severe AD patients (n = 18). All subjects 
were recruited by the Neurology Department of the Hospital, 12 
TaBle 1 | Demographic data and neuropsychological test results of adult and 
elderly healthy subjects, as well as of mild Alzheimer’s disease (mAD) and severe 
Alzheimer’s disease (AD) patients.
adult elderly maD aD
n (F/M) 20 (10/10) 38 (28/10) 26 (15/11) 18 (13/5)
Age (years) 40.32 ± 8.54 74.34 ± 9.22 76.08 ± 7.46 79.10 ± 6.53
MMSE n.e. 29.02 ± 0.7 21.02 ± 0.86 16.44 ± 0.84
CDR n.e. 0 2 3
F, female; M, male; MMSE, Mini-Mental State Examination Score; CDR, Clinical 
Dementia Rating; n.e., not evaluated.
The data of age and of MMSE score are expressed as mean ± SD, but those of CDR 
scores are presented as range values.
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Octubre of Madrid, and were tested by a standardized neuropsy-
chological battery. The AD diagnosis was established according to 
the guidelines of the National Institute on Neurological Disorders 
and Stroke and the Alzheimer’s Disease and Related Disorders 
Association (55). Disease severity and normal cognitive function 
was determined by a clinician’s judgment based on a structured 
interview with the patient and the results of the Clinical Dementia 
Rating and the Mini-Mental State Examination (MMSE) tests (56). 
The mAD stage was established at 20 ≤ MMSE ≤ 23 score and AD 
stage at <18 MMSE score. Inclusion criteria for cognitively nor-
mal elderly healthy subjects were MMSE scores > 27, no history 
or clinical signs of neurological or psychiatric disease or cognitive 
symptoms. Demographic details and MMSE test results of the dif-
ferent study groups are summarized in Table 1. All subjects were 
subjected to a clinical survey and physical examination. Those 
with a history of cardiovascular disease, cancer, or chronic inflam-
matory diseases, as well as individuals with current inflammatory 
alterations (findings of clinical significance in general laboratory 
parameters) were not included in this study. The consent of the 
subjects was obtained according to the Declaration of Helsinki, 
and approval was obtained from the corresponding Research 
Ethic Committees. Written informed consent was obtained from 
all participants or representatives.
collection of Peripheral WB cells and 
isolation of Blood neutrophil and 
lymphocytes cells
Human samples (10 mL) of peripheral blood were collected using 
vein puncture and sodium citrate-buffered Vacutainer tubes (BD 
Diagnostic, Spain). Blood extraction was performed between 
9:00 a.m. and 10:00 a.m. to avoid circadian variations in immune 
parameters. On the one hand, 8 mL of peripheral blood was used 
for isolation of both PMNs (mainly neutrophils) and mononu-
clear (mainly lymphocytes) leukocytes following a previously 
described method (57). Thus, neutrophil and lymphocyte cells 
were isolated using 1.119 and 1.077  g/cm3 density Histopaque 
(Sigma-Aldrich, Spain) separation, respectively. Collected cells 
were counted (95% of viability determined using trypan blue 
staining) and adjusted to the corresponding final concentra-
tions for the development of the different assays of redox state 
and immune functions. The immune functions assays were 
performed with fresh cells, whereas the redox state assays were 
assessed in aliquots of frozen cells. These aliquots were stored 
at −80°C until used. On the other hand, samples of WB  cells, 
which contain the total red blood cells (RBC) together with the 
total leukocyte populations, were obtained following a previ-
ously described procedure (58). For this, 500 µL of the peripheral 
blood sample was diluted with 500  µL of RPMI 1640 medium 
without glutamine (Gibco, Burlington, ON, Canada) and 10 µL 
of gentamicin (0.1 mg/mL in tube). The samples were incubated 
for 4 h at 37°C in a saturated atmosphere of CO2 and humidity. 
Then, samples were centrifuged at 900 × g for 10 min to obtain the 
WB cell pellets after plasma removal. RPMI 1640 with glutamine 
(Gibco) was added to the blood cells to make 1  mL, and then 
several aliquots were prepared for the determination of redox 
state parameters. These aliquots were stored at −80°C until used.
adherent capacity assay
For the measurement of adherence capacity of human peripheral 
blood neutrophils and lymphocytes, we followed a method 
previously described (59) with some slight modifications. This 
method mimics, in  vitro, cellular adherence to endothelium 
in  vivo. Briefly, 500  µL of WB diluted 1:1with Hank’s medium 
was placed in adherence columns consisting of a Pasteur pipet, 
in which 50 mg of nylon fibers was packed to a height of 1.25 cm. 
After 10  min, the effluent had drained by gravity, and neutro-
phils and lymphocytes were counted in this effluent using the 
Neubauer hemocytometer (microscope, 40×). Aliquots of 100 µL 
of 50% diluted WB effluent were mixed with 900  µL of Türk’s 
solution, which has the ability to lyse RBC and differentiate the 
morphology of PMNs and mononuclear leukocytes. Results were 
expressed as the number of cells per mm3. In addition, another 
aliquot of 500 µL of WB diluted 1:1 with Hank’s medium was used 
to count the total number of neutrophils and lymphocytes present 
in WB, as described earlier. The difference between the number 
of leukocytes present in the initial mixture and in the effluent, 
after passing through the adherence column, gives the number 
of adherent cells. The percentage of adherent neutrophils and 
lymphocytes, expressed as Adherence Index (AI), was calculated 
according to the equation:
 
IA leukocytes mm total leukocytes mm effluent
leukocyte
3 3= −( )[ / /
/ s mm total 13/ .(  × 00  
chemotaxis assay
The induced mobility or chemotaxis of peripheral blood isolated 
neutrophils and lymphocytes was carried out following a method 
previously described (57). Boyden chambers with two compart-
ments separated by a polycarbonate filter (3  µm of diameter; 
Millipore, Ireland) were used to evaluate the chemotactic index 
(CI). Aliquots of 300 µL of neutrophil and lymphocyte suspen-
sions (106 cells/mL) in Hank’s medium were deposited in the 
upper compartment, and aliquots of 400 µL of the chemoattract-
ant agent N-formylmethionine-leucyl-phenylalanine (Sigma-
Aldrich) at a concentration of 10−8 M in the lower compartment 
of the chambers. The chambers were incubated for 3 h at 37°C, 
and the filters were fixed and stained with Giemsa’s solution 
(Sigma-Aldrich). The number of neutrophils and lymphocytes 
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on the lower face of the filter was counted in 20 microscope fields 
using an immersion objective (×100) and recorded as CI.
Phagocytosis assay
Phagocytosis of inert particles (latex beads, 1.1  µm diameter, 
Sigma-Aldrich) was assayed in phagocytes (isolated blood neutro-
phils) following a method previously described (57). Neutrophils 
adjusted to 106 cells/mL were incubated on migration inhibition 
factor plates (Kartell, Noviglio, Italy) for 30  min at 37°C in a 
humidified atmosphere. The adherent monolayers obtained were 
washed with prewarmed PBS solution, and then 200 µL of Hank’s 
solution and 20  µL of latex beads (1.1  µm diluted to 1% PBS, 
Sigma-Aldrich) were added. After 30 min of incubation under 
the same conditions, the plates were washed, fixed with methanol 
(50%), and stained with Giemsa’s solution (Sigma-Aldrich). The 
number of particles ingested by 100 neutrophils was counted 
using an immersion objective (×100) and this was expressed as 
phagocytic index, while the number of ingesting neutrophils per 
100 neutrophils was expressed as phagocytic efficiency.
nK cytotoxicity assay
The NK cell cytotoxicity, which is the main antitumoral protec-
tion of the organism, was measured by an enzymatic colorimetric 
assay (Cytotox 96 TM Promega, Boehringer Ingelheim, Germany) 
based on the determination of lactate dehydrogenase (LDH) 
released by the cytolysis of targets cells (human K562 lymphoma 
cells), using tetrazolium salts (57). Briefly, target cells were seeded 
in 96-well U-bottom culture plates (Nunclon, Denmark) at 104 
cells/well in 1640 RPMI without phenol red (Gibco). Effector 
cells (mononuclear leukocyte suspensions adjusted to 106 cells/
mL) were added at 105 cells/well, obtaining an effector/target 
rate of 10/1. The plates were centrifuged at 250 × g for 5 min to 
facilitate cell-to-cell contacts and were incubated for 4 h at 37°C. 
After incubation, LDH activity was measured in 50 μL/well by 
addition of the enzyme substrate with absorbance recording at 
490 nm. The results were expressed as the percentage of tumor 
cells killed (% lysis).
lymphoproliferation assay
The proliferation capacity of lymphocytes was evaluated by a stand-
ard method, previously described (57). The assay was assessed in 
basal and stimulated conditions using the mitogens phytohema-
glutinin (PHA) and lipopolysaccharide (LPS). Aliquots of 200 µL 
of isolated mononuclear leukocyte suspensions adjusted to 106 
cells/mL of complete medium [containing RPMI 1640 enriched 
with l-glutamine and phenol red and supplemented with 10% 
heat-inactivated (56°C, 30  min) fetal calf serum (Hyclone, GE 
Healthcare, USA) and gentamicin (100 mg/mL, Sigma-Aldrich)] 
were dispensed into 96-well plates (Nunclon, Denmark). 20 µL 
of complete medium (basal lymphoproliferation), PHA, or LPS 
(1  µg/mL, Sigma-Aldrich) was added to each well. After 48  h 
of incubation at 37°C in a sterile and humidified atmosphere of 
5% CO2, 2.5 μCi 3H-thymidine (Hartmann Analytic, Germany) 
was added to each well. Previously, 100 µL of culture supernatant 
from each well was collected and stored at −80°C until used for 
cytokine analysis. After another incubation of 24  h, cells were 
harvested in a semiautomatic harvester (Skatron Instruments, 
Norway), and thymidine uptake was measured in a beta counter 
(LKB, Uppsala, Sweden) for 1 min. The results were calculated 
as 3H-thymidine uptake (counts per minute, cpm) for basal and 
stimulated (with mitogens) conditions and also were expressed 
as lymphoproliferation capacity (%) giving 100% to the cpm in 
basal conditions.
glutathione content assay
Both reduced [glutathione (GSH)], the main non-enzymatic 
reducing agent of the organism, and oxidized [oxidized glu-
tathione (GSSG)] forms of glutathione were determined using 
a fluorometric assay previously described (60). This method 
is based on the capacity of reaction that GSSG and GSH show 
with o-phthalaldehyde (OPT, Sigma-Aldrich), at pH 12 and 
pH 8, respectively, resulting in the formation of a fluorescent 
compound. The assay was evaluated in WB cells (containing total 
RBC and leukocyte populations), as well as in isolated peripheral 
blood neutrophils and mononuclear leukocytes. For this, aliquots 
of frozen WB cells (50 µL) were resuspended in phosphate buffer 
0.1  M, pH 7.4 (200  µL) (Sigma-Aldrich), whereas aliquots of 
isolated neutrophils and lymphocytes adjusted to 106 cells/mL in 
Hank’s solution were centrifuged at 1,200 × g for 10 min at 4°C. All 
samples were resuspended in phosphate buffer 50 mM containing 
EDTA 0.1 M, pH 8 (600 µL) (Sigma-Aldrich). Then, samples were 
sonicated, and after the addition of HClO4 (60%, Sigma-Aldrich; 
7.5  µL), they were centrifuged at 9,500 ×  g for 10  min at 4°C. 
Aliquots of supernatants (10  µL) were dispensed into 96-well 
black plates (Nunc). For GSH measurement, 190 µL of phosphate 
buffer and 20 µL of OPT (1 mg/mL in methanol) were dispensed 
in the wells, and the plate was incubated for 15 min in the dark 
and at room temperature. For the measurement of GSSG, 8 µL of 
N-ethylmaleimide (0.04  M; Sigma-Aldrich) was added to each 
well to prevent interference of GSH with GSSG. The plate was 
incubated for 30 min under the same conditions. Then, 186 µL 
of NaOH (0.1 N) and 20 µL of OPT were incorporated, and the 
plate was incubated for 15  min in similar conditions. In both 
GSH and GSSG measurements, the fluorescence emitted by each 
well was measured at 350 nm excitation and 420 nm emission. 
Protein content of the samples was determined following the 
bicinchoninic acid protein assay kit protocol (Sigma-Aldrich), 
using serum albumin (BSA, Sigma-Aldrich) as standard. Results 
were expressed as nanomoles of GSH or GSSG per milligram of 
protein. Moreover, the GSSG/GSH ratio was calculated for each 
sample.
lipid Peroxidation (MDa) assay
The estimation of MDA, in both blood cells and isolated peripheral 
blood neutrophils and mononuclear leukocytes, was evaluated 
using the commercial kit “MDA Assay Kit” (Biovision, Mountain 
View, CA, USA), which measures the reaction of MDA with 
thiobarbituric acid (TBA) and the MDA-TBA adduct formation. 
For this, aliquots of frozen WB cells (100 µL) were resuspended 
in phosphate buffer 0.05 M, pH 7.4 (200 µL), whereas aliquots 
of isolated neutrophils and lymphocytes adjusted to 106 cells/
mL in Hank’s solution were centrifuged at 1,200 × g for 10 min 
at 4°C. All samples were resuspended in lysis buffer (300  µL) 
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containing butylated hydroxytoluene (0.1 mM, 3 µL), sonicated, 
and centrifuged again at 13,000 × g for 10 min. The supernatants 
(200  µL) from each sample were added to TBA (600  µL) and 
incubated at 95°C for 60  min. Samples were cooled in ice for 
10 min, and 200 µL of reaction mixture was mixed with 300 µL 
of n-butanol (Sigma-Aldrich) to create an organic phase in which 
the MDA molecules were to be placed. Samples were centrifuged 
10  min at 13,000 ×  g at room temperature, and 200  µL of the 
supernatants (upper organic phase) was collected and dispensed 
into a 96-well microplate for spectrophotometric measurement at 
532 nm. MDA supplied in the kit was used as standard, and MDA 
levels were determined by comparing the absorbance of samples 
with that of the standards. Protein concentration of the samples 
was measured as described earlier. Results were expressed as 
nanomoles of MDA per milligram of protein.
cytokine Measurement
The IL-6, TNF-α, and IL-10 release was measured in culture 
supernatants of WB in the absence or presence of LPS follow-
ing a method previously described (58). Briefly, 500 µL of blood 
was diluted 1:1 with RPMI 1640 medium without l-glutamine 
(Gibco) and incubated for 4  h with 10  µL gentamicin (1  mg/
mL, Sigma-Aldrich) and 10 µL LPS (250 ng/mL, Sigma-Aldrich) 
or 10 µL RPMI 1640 medium (basal conditions). Samples were 
centrifuged, and supernatants were collected and frozen at −20°C 
until assay. Levels of IL-6, TNF-α, and IL-10 were measured 
simultaneously by multiplex luminometry (Beadlyte human mul-
tiplex cytokine detection system, HCYTOMAG-60K, Millipore, 
Billerica, MA, USA), with minimum detectable doses of IL-6, 
TNF-α, and IL-10 under 0.9, 0.7, and 1.1 pg/mL, respectively. The 
results were expressed as picograms per milliliter.
statistical analysis
Statistical analysis was performed in SPSS IBM, version 21.0 
(SPSS, Chicago, USA). All tests were two-tailed, with a sig-
nificant level of α = 0.05. Data are presented as mean ± standard 
deviation (SD). Normality of the samples and homogeneity of 
the variances were checked by the Kolmogorov–Smirnov test and 
Levene test, respectively. Differences due to age and AD pathol-
ogy were studied using a one-way analysis of variance followed 
by post hoc tests analysis or the non-parametric Kruskal–Wallis 
test. The Tukey test was used for post  hoc comparisons when 
variances were homogeneous, whereas its counterpart analysis 
Games-Howell was used with unequal variances when they were 
not homogeneous. Figures were built using GraphPad Prism 6.
resUlTs
immune Functions in Peripheral Blood 
neutrophils and Mononuclear leukocytes 
of maD and aD Patients as Well as 
healthy controls
The results obtained in the immune functions studied in isolated 
human blood neutrophils and mononuclear cells obtained from 
adult and older healthy subjects, as well as from mAD and AD 
patients are shown in Figure  1 and Table  2. In general, all the 
immune parameters analyzed in the present work (adherence, 
chemotaxis, and phagocytosis of neutrophils as well as adherence, 
chemotaxis and proliferative response of lymphocytes in both basal 
and stimulated conditions, and the antitumor cytotoxic activity of 
NK cells) have been shown to deteriorate in aging and AD pathol-
ogy. However, a different pattern of impaired immune function 
has been observed between the early and advanced stages of AD.
In elderly healthy subjects, in comparison with healthy adults, 
statistically significant lower values in neutrophil chemotaxis 
(P < 0.001; Figure 1C) and phagocytosis (176 ± 13 and 488 ± 25 
P.I., older vs adult, respectively; P < 0.001), as well as in the activ-
ity of NK  cells (P <  0.01; Figure  1E), lymphocyte chemotaxis 
(P <  0.05; Figure  1D) and PHA- and LPS-lymphoproliferative 
response (P < 0.001; Figures 1G,H; Table 2) were obtained. In 
contrast, higher values were also shown in old subjects in neutro-
phil and lymphocyte adherence (P < 0.01; Figures 1A,B), as well 
as in basal proliferation (P < 0.01; Figure 1F).
Regarding AD pathology, there were significant differences 
in AD patients relative to elderly healthy controls of the same 
chronological age, as well as in mAD compared to the same 
controls. Thus, AD patients exhibited higher basal proliferation 
(P  <  0.05; Figure  1F) and lower neutrophil and lymphocyte 
chemotaxis (P  <  0.05; Figures  1C,D), as well as PHA- and 
LPS-lymphoproliferative response (P  <  0.05; Figures  1G,H; 
Table  2) in comparison to elderly subjects. Interestingly, at the 
early stage of the disease, mAD patients also showed lower PHA-
lymphoproliferation (P < 0.01; Figure 1G; Table 2) than elderly 
subjects. However, mAD exhibited a significant increase in neutro-
phil (P < 0.01; Figure 1A) and lymphocyte (P < 0.001; Figure 1B) 
adherence in relation to elderly subjects, which was not observed at 
the advanced stage of AD. Finally, it should be noted that immune 
function differences between the early and advanced stages of AD 
were also observed. Thus, AD patients showed significantly lower 
neutrophil and lymphocyte adherence (P < 0.05; Figures 1A,B), as 
well as lower chemotaxis of lymphocytes and lower NK cytotoxic 
activity (P < 0.05; Figures 1D,E) than mAD patients.
cytokine Production in response to lPs 
stimulation in Blood leukocytes of maD 
and aD Patients as Well as healthy 
controls
Cytokines are major mediators of the complex interactions 
among immune cells, being responsible for the development 
and resolve of immune response. Aging is characterized by a 
chronic low-grade inflammatory state (61), and the maintenance 
of health relies on the adequate balance of anti-inflammatory 
and pro-inflammatory compounds (28). For this reason, we 
analyzed the levels of pro-inflammatory (IL-6 and TNF-α) and 
anti-inflammatory (IL-10) cytokines secreted ex vivo by blood 
cells incubated for 4 h under LPS-stimulated conditions, in mAD 
and AD patients, as well as in adult and elderly healthy subjects. 
The IL-10/TNF-α ratios, which are a good indicator of successful 
aging and longevity (30), were also calculated.
In general, the results of our study showed that the release 
of these cytokines suffers impairments with aging. Moreover, 
FigUre 1 | Function parameters in isolated peripheral blood neutrophils and mononuclear cells of mild Alzheimer’s disease (mAD) and Alzheimer’s disease (AD) 
patients, as well as of adult and elderly healthy subjects. Adherence (%) of neutrophils (a) and lymphocytes (B); chemotaxis index (C.I.) of neutrophils (c) and 
lymphocytes (D); natural killer (NK) cytotoxicity (% lysis) (e); proliferation of lymphocytes in basal conditions [48 h incubation; counts per minute (cpm)] (F); 
proliferation of lymphocytes (48 h incubation; cpm) in response to phytohemagglutinin (PHA, 1 µg/mL) (g) and in response to lipopolysaccharide (LPS, 1 µg/mL) (h). 
Data are shown as the mean (horizontal bar) of 18–38 values corresponding to the number of subjects analyzed in each group (20 adult, 38 elderly, 26 mAD, and 18 
AD). Each value is the mean of duplicate assays. a: P < 0.05, aa: P < 0.01, and aaa: P < 0.001 with respect to the value in adult subjects; b: P < 0.05, bb: 
P < 0.01, and bbb: P < 0.001 with respect to the value in elderly subjects; c: P < 0.05 with respect to the value in mAD patients.
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FigUre 2 | Levels (pg/mL) of cytokines released after 4 h of culture in the presence of lipopolysaccharide (1 µg/mL) by peripheral whole blood cells of mild 
Alzheimer’s disease (mAD) and Alzheimer’s disease (AD) patients, as well as of adult and elderly healthy subjects. Interleukin (IL)-6 (a), tumor necrosis factor (TNF)-α 
(B), and IL-10 (c), as well as IL-10/TNF-α ratios (D). Data are shown as the mean (horizontal bar) of the values corresponding to the number of subjects analyzed in 
each group (20 adult, 18 elderly, 18 mAD, and 18 AD). Each value is the mean of duplicate assays. a: P < 0.05, aa: P < 0.01, and aaa: P < 0.001 with respect to 
the value in adult subjects; b: P < 0.05 and bb: P < 0.01 with respect to the value in elderly subjects; and c: P < 0.05 and cc: P < 0.01 with respect to the value in 
mAD patients.
TaBle 2 | Stimulation of proliferation (%) in response to phytohemagglutinin and 
lipopolysaccharide (1 µg/mL), in isolated peripheral mononuclear cells of adult 
and elderly healthy subjects, as well as of mild Alzheimer’s disease (mAD) and 
severe Alzheimer’s disease (AD) patients.
lymphoproliferation 
(% stimulation)
adult elderly maD aD
PHA (%) 1,950 ± 232 391 ± 56a 198 ± 19a,b 218 ± 36a,c
LPS (%) 346 ± 25  176 ± 13d 156 ± 12c,e 167 ± 17e
Data are expressed as mean ± SD of the values corresponding to 20 adult, 38 elderly, 
26 mAD, and 18 AD subjects. Each value is the mean of duplicate assays.
aP < 0.001 with respect to the value in adult subjects.
bP < 0.01 with respect to the value in elderly subjects.
cP < 0.05 with respect to the value in elderly subjects.
dP < 0.05 with respect to the value in adult subjects.
eP < 0.01 with respect to the value in adult subjects.
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also accompanied by a marked decrease in IL-10 and the IL-10/
TNF-α ratio (P < 0.001; Figures 2C,D). A similar cytokine profile 
was also observed in AD patients in relation to older subjects. 
Thus, AD patients had higher levels of IL-6 and TNF-α (P < 0.01; 
Figures 2A,B), as well as lower IL-10 release and IL-10/TNF-α 
ratios (P < 0.05; Figures 2C,D) than elderly controls. However, 
mAD patients only showed a significant increase in the levels of 
IL-6 (P < 0.05; Figure 2A). No differences were observed in TNF-α 
and IL-10 release and IL-10/TNF-α ratios between mAD and 
older subjects. Regarding the differences between the different 
stages of AD, it is important to note that AD patient exhibited a 
higher IL-6 LPS-induced release (P < 0.05; Figure 2A) and a lower 
IL-10/TNF-α ratio (P < 0.05; Figure 4D) than mAD patients.
Oxidative stress and Damage Parameters 
in isolated Peripheral Blood neutrophils 
and Mononuclear cells of maD and aD 
Patients as Well as healthy controls
A good maintenance of the redox state is vital for the proper 
functioning of immune cells, and thus the oxidative stress, which 
a similar pattern of altered secretion was observed for all 
investigated cytokines, in AD patients. As shown in Figure  2, 
under LPS-stimulated conditions, increased levels of IL-6 and 
TNF-α (P < 0.05 and P < 0.001, respectively; Figures 2A,B) were 
observed in the elderly subjects in comparison to adults. This was 
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is the basis of aging and age-related diseases, is detrimental for 
leukocyte functions (28). Hence, the decline in immune response 
observed in mAD and AD patients could be mediated by an 
increase in oxidative stress and the consequent oxidative damage. 
To test this possibility, the intracellular content of GSH and GSSG, 
the GSSG/GSH ratio (one of the best markers of oxidative stress), 
as well as the MDA levels (one of the major lipid peroxidation 
products) were assessed in isolated human blood neutrophils and 
mononuclear cells obtained from mAD and AD patients, as well 
as from adult and elderly healthy subjects. The results are shown 
in Figure 3. In general, in both leukocyte populations a higher 
oxidative stress and damage have been shown in elderly subjects 
and AD patients than in adult controls. However, a different pat-
tern of impaired redox state has been observed between the early 
and advanced stages of AD, the neutrophils showing a greater 
oxidative stress and damage than the lymphocytes.
Regarding aging, elderly healthy controls showed in their 
neutrophils and lymphocytes significantly lower GSH contents 
(P < 0.05 and P < 0.01, respectively; Figures 3A,B), as well as 
higher GSSG amounts (P < 0.01; Figures 3C,D), higher GSSG/
GSH ratios (P < 0.01 and P < 0.05, respectively; Figures 3E,F), and 
MDA levels (P < 0.01 and P < 0.05, respectively; Figures 3G,H) 
in relation to adult subjects.
Regarding the AD pathology, AD patients had in their neu-
trophils a marked increase in both GSSG and MDA contents 
(P < 0.01; Figures 3C,G), as well as in GSSG/GSH ratios (P < 0.05; 
Figure 3E) in comparison to elderly subjects, accompanied also 
by a marked decrease in the levels of GSH (P < 0.05; Figure 3A). 
However, in the case of lymphocytes, AD patients showed higher 
GSH contents (P < 0.05; Figure 3B) than elderly controls, whereas 
no differences were observed in the other parameters analyzed. 
Likewise, similar results were observed in mAD patients, who 
showed higher GSSG contents, GSSG/GSH ratios, and MDA 
levels (P < 0.05; Figures 3C,E,G) in neutrophils as well as higher 
GSH contents (P <  0.01; Figure  3B) in lymphocytes, than the 
corresponding values in elderly controls. In relation to the dif-
ferent stages of AD, it is important to note that AD patients had 
in their neutrophils markedly increased GSSG/GSH ratios and 
MDA levels (P < 0.05; Figures 3E,G) as well as decreased GSH 
contents in their lymphocytes (P < 0.05; Figure 3B) in relation 
to mAD patients.
Oxidative stress and Damage Parameters 
in human Peripheral Blood cells of maD 
and aD Patients as well as of healthy 
controls
It is known that there is a significant difference between the 
use of WB and purified and isolated PMNs and mononuclear 
leukocytes (62). Moreover, various peripheral blood cell types 
and their proportions can affect the immune response, as well 
as the inflammatory and oxidative stress conditions (54, 62). For 
this reason, the same parameters of oxidative stress and damage 
analyzed in isolated neutrophils and lymphocytes from mAD and 
AD patients, and adult and elderly healthy subjects, were also 
evaluated using samples of WB cells, containing both total RBC 
and leukocyte populations. This kind of sample better reproduces 
the in vivo conditions. The results are shown in Figure 4. There 
were higher values of oxidative stress and damage in blood cells 
of elderly subjects than in those of adults. Thus, GSH values 
were lower (P < 0.001; Figure 4A) and GSSG/GSH ratios higher 
(P < 0.05; Figure 4C), as well as both GSSG (P < 0.01; Figure 4B 
and MDA (P <  0.001; Figure  4D) levels, than those in adult 
subjects.
Regarding AD pathology, AD patients exhibited, in their blood 
cells, significantly lower GSH contents (P <  0.05; Figure  4A), 
higher GSSG and MDA contents (P < 0.05 and P < 0.001, respec-
tively; Figures 4B,D), and GSSG/GSH ratios (P < 0.05; Figure 4C) 
than elderly subjects. Similar results were also observed in mAD 
patients in relation to elderly subjects, which also showed lower 
GSH levels (P < 0.01; Figure 4A) and higher GSSG/GSH ratios 
(P < 0.05; Figure 4C) and MDA contents (P < 0.01; Figure 4D) 
than elderly controls. However, no differences were observed 
in GSSG contents between mAD and elderly subjects. Finally, 
regarding the differences between early and advanced stages 
of AD, it is important to note that AD patients showed higher 
levels of GSSG and MDA (P < 0.05 and P < 0.01, respectively; 
Figures 4B,D) than mAD patients.
Basal cytokine Production in Blood 
leukocytes of maD and aD Patients as 
well as of healthy controls
Since an age-related increase in release of pro-inflammatory 
cytokines in resting cells leads to a sterile inflammation (30), and 
this alteration of the inflammatory status in aging (“inflamm-
aging”) could lead to a chronic situation causing neuronal 
impairment and loss associated with AD (63), we also assessed 
extracellular release of IL-6, TNF-α, and IL-10 secreted ex vivo by 
blood cells cultured (4 h) under resting conditions, from mAD 
and AD patients, as well as from adult and elderly healthy controls.
As shown in Table  3, under basal conditions, in elderly 
subjects the values of IL-6 and TNF-α released were higher 
(P < 0.01 and P < 0.05, respectively) than in adults. Regarding 
AD pathology, a similar cytokine profile was also observed in AD 
patients in relation to both adults and elderly subjects. Thus, AD 
patients showed higher levels of IL-6 and TNF-α (P < 0.05) than 
elderly controls, whereas mAD patients only showed statistically 
significant higher values (P <  0.05) in the TNF-α levels. Basal 
IL-10 release was not detectable by the multiplex, so the IL-10/
TNF-α ratio could not be calculated. Interestingly, regarding dif-
ferences between early and advanced stages of AD, AD patients 
showed higher basal IL-6 release (P < 0.05) than the individuals 
with mAD.
DiscUssiOn
To our knowledge, this is the first study that analyzed the changes in 
several parameters of function and oxidative-inflammatory stress 
state in different types of peripheral blood immune cells, such as 
neutrophils and mononuclear cells, from patients with mild and 
severe AD, compared with a healthy age-matched control group 
of subjects without cognitive impairment. Additionally, all these 
parameters were also studied in healthy adult subjects to evaluate 
FigUre 3 | Oxidative stress parameters and lipid peroxidation in isolated peripheral blood neutrophils and mononuclear cells of mild Alzheimer’s disease (mAD) and 
Alzheimer’s disease (AD) patients, as well as of adult and elderly healthy subjects. Intracellular reduced glutathione (GSH) contents (nmol/mg protein) in neutrophils 
(a) and lymphocytes (B); intracellular oxidized glutathione (GSSG) contents (nmol/mg protein) in neutrophils (c) and lymphocytes (D); GSSG/GSH ratios in 
neutrophils (e) and lymphocytes (F); and intracellular malondialdehyde (MDA) contents (nmol/mg protein) in neutrophils (g) and lymphocytes (h). Data are shown as 
the mean (horizontal bar) of 9–12 values corresponding to the number of subjects analyzed in each group (9 adult, 10 elderly, 11 mAD, and 12 AD). Each value is 
the mean of duplicate assays. a: P < 0.05 and aa: P < 0.01 with respect to the value in adult subjects; b: P < 0.05 and bb: P < 0.01 with respect to the value in 
elderly subjects; and c: P < 0.05 with respect to the value in mAD patients.
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TaBle 3 | Levels of interleukin (IL)-6 and tumor necrosis factor (TNF)-α (pg/mL) 
released by peripheral whole blood cells of adult and elderly healthy subjects, as 
well as of mild Alzheimer’s disease (mAD) and severe Alzheimer’s disease (AD) 
patients, after 4 h of culture in basal conditions.
Basal 
cytokines
adult elderly maD aD
IL-6  
(pg/mL)
8.89 ± 1.93 16.23 ± 4.72a 16.21 ± 3.84a 21.60 ± 5.17b, c,d
TNF-α  
(pg/mL)
 24.76 ± 6.14  40.30 ± 14.89e  90.76 ± 26a,c 105.8 ± 22.5a,c
Data are expressed as mean ± SD of the values corresponding to 10 adult, 10 elderly, 
8 mAD, and 8 AD subjects. Each value is the mean of duplicate assays.
aP < 0.01 with respect to the value in adult subjects.
bP < 0.001 with respect to the value in adult subjects.
cP < 0.05 with respect to the value in elderly subjects.
dP < 0.05 with respect to the value in mAD patients.
eP < 0.05 with respect to the value in adult subjects.
FigUre 4 | Oxidative stress parameters and lipid peroxidation in whole blood cells (containing both total red blood cells and leukocyte populations) of mild 
Alzheimer’s disease (mAD) and Alzheimer’s disease (AD) patients, as well as of adult and elderly healthy subjects. Intracellular reduced glutathione (GSH) contents 
(nmol/mg protein) (a); intracellular oxidized glutathione (GSSG) contents (nmol/mg protein) (B); GSSG/GSH ratios (c); and intracellular malondialdehyde (MDA) 
contents (nmol/mg protein) (D). Data are shown as the mean (horizontal bar) of 11–15 values corresponding to the number of subjects analyzed in each group (13 
adult, 15 elderly, 13 mAD, and 13 AD). Each value is the mean of duplicate assays. a: P < 0.05, aa: P < 0.01, and aaa: P < 0.001 with respect to the value in adult 
subjects; b: P < 0.05, bb: P < 0.01, and bbb: P < 0.001 with respect to the value in elderly subjects; and c: P < 0.05 and cc: P < 0.01 with respect to the value in 
mAD patients.
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the differences due to the aging process. Our results revealed an 
impairment of the immune functions of both neutrophils and 
mononuclear cells at different stages of AD. Several alterations 
were only observed in severe AD patients and some only in 
mAD patients. Furthermore, our results also demonstrated that 
immune blood cells from mAD and AD patients, and especially 
neutrophils, showed an increased oxidative stress and oxidative 
damage in relation to elderly subjects. This altered redox balance 
could be mediated by the higher production of pro-inflammatory 
cytokines, which has been also observed in AD patients.
The immune system has a profound implication in the pathol-
ogy of AD, not only at the central level but also at the peripheral 
level (8–10, 17, 19). Although several studies have reported altera-
tion of both innate and acquired immunity at different stages of 
AD (12), there are many contradictory results (11–15, 17). 
Moreover, most of these studies in human and animal models 
have focused on the alteration of the adaptive immune response. 
However, little is known about the changes in innate immunity, 
especially those carried out by phagocytes (e.g., neutrophils). Our 
findings revealed that severe AD patients show lower neutrophil 
and lymphocyte chemotaxis, PHA- and LPS-lymphoproliferation, 
as well as higher basal lymphoproliferation in comparison to 
elderly healthy subjects. These AD-related changes are similar to 
those with aging (28, 30), which was also observed in the present 
study, although more exacerbated. This shows the presence of a 
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lesser competent immune system in severe AD patients than in 
elderly subjects, which could contribute to the high mortality of 
these individuals. Our results agree with some of those observed 
in humans and experimental animals with AD (11, 16, 17, 26, 
33, 52). Thus, leukocytes of 3xTg-AD mice presented an 
impairment of chemotaxis capacity (16, 26, 52). In relation to 
lymphoproliferative response in stimulated conditions some 
studies also report a decrease in this function in cells obtained 
from patients with severe AD (11, 17, 33, 64).
Surprisingly, mAD patients, but not severe AD patients, 
showed higher values in neutrophil and lymphocyte adherence 
than elderly subjects. This increase in adherence is a characteristic 
of aging (24, 28). Although at this moment we cannot explain the 
possible regulation mechanisms that severe AD patients use to 
present similar values to age-matched controls, this parameter 
could be an early marker of the appearance of AD. In mAD 
patients, a lower proliferative response of lymphocytes to the 
mitogen PHA than in elderly subjects also occurred. Thus, this 
function of lymphoproliferative response to mitogens, which 
typically decreases with aging (24, 28, 30) appeared even lower 
in cells of mAD and AD.
Alzheimer’s disease patients in comparison to mAD showed 
lower lymphocyte chemotaxis and antitumoral NK activity. In this 
regard, although limited in number, several studies in human and 
3xTg-AD mice revealed that these immune function parameters 
were altered in AD (16, 26, 32, 52). Thus, NK cell activity, which 
has been proposed as one biomarker of immune alterations in 
the progression of AD (32) and which was decreased in cells of 
3xTg-AD mice in advanced stages of AD (16, 26), was lower in 
severe AD than in mAD patients. In the case of chemotaxis of 
lymphocytes, a function that decreases with aging (28, 30), our 
results reflect a clear deterioration of this activity in AD patients, 
even higher than shown by cells of elderly subjects and of mAD. 
Thus, this parameter could be considered as a possible marker of 
the progression of the disease.
Interestingly, it should be noted that although the decline of 
the immune functions showed with aging were also observed in 
mAD and AD patients, several of these immunological altera-
tions were greatly exacerbated in individuals with severe AD in 
comparison to healthy elderly subjects of the same chronological 
age. This suggests that AD patients suffer an accelerated immu-
nosenescence. Thus, since these immune function parameters are 
good markers of health and predictors of longevity (28, 30), these 
could be used as peripheral biomarkers of the progression of AD.
A chronic oxidative-inflammatory stress, a condition in 
which oxidant and pro-inflammatory compounds overwhelm 
antioxidant and anti-inflammatory defenses, is associated with 
aging and several age-related pathologies (26, 28). Indeed, several 
studies in human and animal models, including some by our 
group, have demonstrated that increased peripheral oxidative 
stress markers are associated with aging and, more specifically, 
with AD (16, 26, 30, 47, 52, 54). In AD, oxidative stress has been 
recognized as an essential contributor to the pathogenesis and 
progression of the disease (38, 40, 52, 65). As occurs in the brain 
(7, 40), an enhanced oxidative stress during AD is also present 
in peripheral blood cells (27, 41–43). Most studies have focused 
on mononuclear cells, mainly in lymphocytes, which reflect the 
pathological oxidative stress conditions observed in the brains of 
AD patients. These studies found an elevated production of oxi-
dative compounds, lipid oxidation, DNA damage, mitochondrial 
susceptibility, basal apoptosis as well as altered levels of antioxi-
dant enzymes in lymphocytes of AD patients, as well as even in 
those of MCI subjects, in comparison with these cells of healthy 
subjects (27, 66–68). These results suggest that some of these 
parameters could be prodromal markers of AD. However, little 
is known about the changes in the redox balance of neutrophils 
during the progression of AD. Therefore, since phagocytes may 
be the immune cells that contribute most to the oxidative stress 
and damage associated with immunosenescence (28, 54), we also 
analyzed different redox state and oxidative damage parameters 
in both isolated peripheral blood neutrophils and mononuclear 
cells, in order to elucidate possible differences between them. 
Interestingly, our results showed that neutrophils suffer a marked 
increased oxidative stress and damage during the progression of 
AD. In particular, the neutrophils of both mAD and AD patients 
had lower antioxidant GSH contents and higher oxidant markers, 
such as GSSG and MDA contents, as well as GSSG/GSH ratios, 
than elderly subjects. Nevertheless, this redox state alteration was 
not observed in mononuclear cells, which paradoxically showed 
higher GSH levels in individuals with mild and severe AD than 
those observed in age-matched controls. In this context, it has 
been suggested that in early states of the disease, individuals 
developing AD can suffer a situation of “reductive stress” as a 
result of the activation of a compensatory response to cope with 
a high exposure of oxidant compounds (40). Therefore, target-
ing reductive stress may be a strategy to delay and prevent the 
onset and progression of AD (69). Thus, it is plausible that an 
overexpression and high levels of GSH could be induced by an 
increased oxidant production in lymphocytes of mAD patients. 
Nevertheless, these levels were lower in severe AD patients in 
comparison to mAD subjects. The glutathione cycle is one of the 
main intracellular mechanisms to preserve a competent intracel-
lular redox state (70). The role of this has been extensively studied 
in AD, in both humans and animal models, where a depletion in 
GSH contents and an imbalance in GSSG/GSH ratios in favor 
of GSSG have been noted at central (39) and peripheral levels, 
such as in plasma, peritoneal leukocytes, and blood cells (47, 
52, 71). Moreover, it has been described that the altered levels 
of these circulating compounds are also directly related to the 
severity of cognitive impairment (47, 67). The imbalance in 
GSSG/GSH ratios could be the result of a defective respiratory 
chain caused by the activation of Aβ peptide on its complexes, 
which leads to overproduction of oxidant compounds, which has 
also been observed in peripheral leukocytes (72). In addition, an 
adequate immune response will require optimal levels of GSH 
(70). Therefore, the lower GSH observed in neutrophils of AD 
could contribute to the impairment of the functions of these cells.
Since the brain is very susceptible to oxidative damage (36), 
lipid peroxidation is one of the most promising procedures in 
AD diagnosis (47). Thus, higher MDA content has been reported 
in the brain and the peripheral levels (e.g., plasma/serum, eryth-
rocytes, and peripheral leukocytes) of not only AD patients but 
also MCI subjects (42, 46, 47). Some authors suggested that lipid 
peroxidation could be one of the main factors responsible for 
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cognitive deterioration and that there was a negative correlation 
between MDA and MMSE scores (43). Others reported that the 
differences depended on the stage of AD (42, 43, 47). However, 
although no difference between moderate and advanced AD was 
detected (46), our results showed that MDA levels in neutrophils 
were higher in patients at the advanced stage of the disease than 
in elderly controls and even in mAD. Thus, this parameter could 
be a useful marker of early stage of AD as well as progression of 
the disease.
Given the different pattern observed in the oxidative stress and 
damage parameters between neutrophils and mononuclear cells 
in the progression of AD, we have also analyzed these parameters 
in WB  cells. This kind of sample better reproduces the in  vivo 
conditions of immune response. Interestingly, a similarly altered 
redox state and oxidative damage pattern were observed in 
WB cells to that in neutrophils. Thus, mAD and AD patients, in 
general, showed lower GSH and higher GSSG contents and GSSG/
GSH ratios, together with a marked increase in MDA levels, than 
cells from elderly subjects. Moreover, it is important to highlight 
that AD patients had a higher GSSG/GSH ratios, as well as GSSG 
and MDA contents, in their neutrophils and WB cells than mAD 
patients. The results suggest that the estimation of these param-
eters in WB cells would be a useful biomarker in the assessment 
of AD progression. Moreover, WB samples are clinically more 
feasible, reproducible, cost effective, easy to implement and apply, 
compared to purified and isolated neutrophils and mononuclear 
blood leukocytes.
In addition, since oxidation and inflammation processes are 
able to induce and exacerbate one another (36), the higher oxida-
tive stress and damage observed in WB cells from mAD and AD 
patients could also be triggered by an increase in basal inflam-
mation. Given that previous works supported the importance of 
cytokines in mediating the activity of peripheral immune cells 
in AD (73, 74), we also assessed the release of IL-6, TNF-α, and 
IL-10 ex vivo by blood cells cultured under resting conditions. 
Our results showed that mAD and AD patients had a higher 
basal TNF-α than elderly subjects, whereas basal IL-6 levels only 
were significantly higher in severe AD. Basal IL-10 release was 
not detectable. Even though cytokine levels are hard to detect 
at basal conditions, due to their short half-life, several studies 
also investigated these inflammatory markers in CSF, serum and 
plasma at different stages of the AD patients (73–76). Although 
the results are controversial, a strong upregulation of pro-
inflammatory cytokines has been observed in these patients, but 
also in MCI (73, 74, 76, 77). Furthermore, these patients showed 
higher plasma levels of IL-6 than those at an early stage of disease 
and healthy controls (77). This agrees with our results, in which 
severe AD patients also showed higher IL-6 release than mAD. 
Interestingly, given that increased basal IL-6 levels in plasma have 
been shown to be a risk for decline in cognitive functions (73), 
as well as being described as one the most powerful predictors of 
morbidity and mortality in the elderly (30), these results suggest 
the possibility of using peripheral IL-6 production as a helpful 
tool to characterize immune dysfunction during AD progression.
The chronic oxidative-inflammatory stress situation observed 
in blood cells of AD patients could be involved in the impairment 
of their functions. Thus, the higher oxidative stress in severe AD 
patients could be the underlying mechanism for the decrease in 
PHA- and LPS-induced lymphoproliferation, as well as for the 
increase in the basal proliferation. This basal proliferation, which 
has scarcely been studied, was also increased with aging (30), as 
well as in the leukocytes of 3xTg-AD mice (52). The higher levels 
of basal proliferation in AD lymphocytes show an overactiva-
tion of these cells. This could be due to the increase age-related 
accumulation of damage-associated molecular patterns, which, 
through the production of pro-inflammatory cytokines, may 
be responsible for the activation of the immune system and the 
establishment of “sterile inflammation” (78). In addition, after a 
mitogenic LPS-stimulus, immune blood cells from AD patients 
also produced a higher release of IL-6 and TNF-α, as well as 
lower IL-10 levels and, consequently, a lower IL-10/TNF-α ratio, 
compared to age-matched controls. This reaffirms the existence of 
an altered immune response in advanced stages of AD. Although 
data on peripheral cytokines in AD patients are controversial 
(73, 74), several authors also found an upregulation of these 
cytokines in LPS-stimulated WB in AD patients in relation to 
elderly controls (75), as also occurred in samples of brain, serum, 
and other cell cultures (79). A possible explanation would be 
that βA peptide, which can activate the overproduction of pro-
inflammatory cytokines (e.g., TNF-α, IL-1β, etc.) in peripheral 
blood monocytes (80, 81), could lead to an abnormal inflam-
matory response. This could be attributed either to an adaptive 
control on innate immunity and/or a compensatory mechanism 
for the lack of effectiveness of adaptive immunity (81). Our 
results also demonstrated an altered balance in the IL-10/TNF-α 
ratios, which showed similar values in mAD patients and elderly 
subjects, whereas the values were lower in AD patients. Since 
this IL-10/TNF-α ratio has been proposed as an indicator of suc-
cessful aging and longevity (30), its determination also may be 
a helpful parameter for evaluating the progression of AD. Since 
the decline in PHA-lymphoproliferation and the high release of 
IL-6 after LPS stimulation not only occur in severe AD patients 
but also begin to decline in mAD patients, this suggests that both 
parameters could be used as possible early peripheral biomarkers 
of AD.
In conclusion, the present study shows the impairment of 
several immune functions of human peripheral blood neutro-
phils and mononuclear cells at different stages of AD. However, 
a different pattern of altered immune response was observed 
between mild and severe AD patients. Thus, several alterations 
were only observed in severe AD patients (e.g., chemotaxis, 
basal, and LPS lymphoproliferation) and others (e.g., adherence) 
only in individuals with mAD. Other alterations detected in the 
mild stage of the disease increased in the late stage (e.g., PHA 
lymphoproliferation and IL-6 release). As occurs in aging, this 
impairment of immune cell functions could have as their basis an 
oxidative-inflammatory stress situation. Thus, our findings also 
demonstrated that several peripheral oxidative stress and dam-
age markers were increased in immune blood cells from mAD 
and AD patients, especially in neutrophils (e.g., low GSH levels, 
high GSSG/GSH ratios, and GSSG and MDA contents), in rela-
tion to elderly subjects. However, this increased oxidative stress 
and damage were higher in severe AD patients than in mAD 
and could be mediated by the higher production of peripheral 
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pro-inflammatory cytokines in these patients. Furthermore, the 
fact that neutrophils showed higher oxidative stress and damage 
than mononuclear leukocytes supports the idea that phagocytes 
are the immune cells that most contribute to the peripheral 
chronic oxidative stress and damage associated with AD, espe-
cially in the advance stages of the disease. Therefore, our results 
support the idea that severe AD patients show an accelerated 
immunosenescence due to the parameters of function and redox 
state studied, these being greatly deteriorated in these patients 
in comparison to elderly subjects of the same chronological age. 
Therefore, since WB cells are very easy to obtain and reproduce 
the results observed in neutrophils, the assessment of oxidative 
stress and damage parameters, as well as peripheral cytokine 
release, together with the analysis of several functions in isolated 
neutrophils and mononuclear cells, would be useful markers of 
AD progression. Nevertheless, additional studies are needed to 
identify function and oxidative-inflammatory stress alterations 
in peripheral blood phagocytes and lymphocytes, especially in 
subjects with mild cognitive deterioration in order to identify 
potential prodromal and preclinical biomarkers of AD.
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